Stoke CEO exits; Medicare drug price talks advance [Yahoo! Finance]
Stoke Therapeutics, Inc. (STOK)
Last stoke therapeutics, inc. earnings: 11/12 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Today, a brief rundown of news involving executive changes at Stoke Therapeutics and the Centers of Medicare and Medicaid Services, as well as updates from Incyte, Precision BioSciences and AstraZeneca that you may have missed. Edward Kaye , CEO of genetic medicines developer Stoke Therapeutics , will step down on Wednesday and be replaced on an interim basis by Ian Smith , a company board member and former chief financial officer at Vertex Pharmaceuticals . Board Chairman Arthur Tzianabos has been appointed to interim executive chairman. Stoke didn't disclose a reason for the change-ups, which come on the heels of a licensing agreement with Biogen . Tzianabos did note that he thinks Smith will provide “continuity” and sup
Read more
Impact Snapshot
Event Time:
STOK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STOK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STOK alerts
High impacting Stoke Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
STOK
News
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.MarketBeat
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $24.00 price target on the stock.MarketBeat
- Stoke Therapeutics Stock Slips as CEO Steps Down [Yahoo! Finance]Yahoo! Finance
- Stoke Therapeutics, Inc. (NASDAQ: STOK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $22.00 price target on the stock.MarketBeat
- Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdatesBusiness Wire
STOK
Earnings
- 11/5/24 - Beat
STOK
Sec Filings
- 3/20/25 - Form 4
- 3/20/25 - Form 4
- 3/20/25 - Form 4
- STOK's page on the SEC website